DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
Capital infusion to accelerate Earendil’s R&D platform
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
This marks the second indication for which gumokimab has gained NDA review acceptance
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Subscribe To Our Newsletter & Stay Updated
